Enliven Therapeutics ELVN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's total liabilities?
- Enliven Therapeutics (ELVN) reported total liabilities of $11.49M in Q1 2026.
- How has Enliven Therapeutics's total liabilities changed year-over-year?
- Enliven Therapeutics's total liabilities decreased by 19.5% year-over-year, from $14.27M to $11.49M.
- What is the long-term trend for Enliven Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Enliven Therapeutics's total liabilities has grown at a 20.9% compound annual growth rate (CAGR), from $6.41M to $16.57M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.